Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19,389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Liu S, Zhou F, Liu Z, Xiong A, Jia Y, Zhao S, Zhao C, Li X, Jiang T, Han R, Qiao M, Liu Y, He Y, Li J, Li W, Gao G, Ren S, Su C, Zhou C. Liu S, et al. Among authors: zhou f, zhou c. Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066. doi: 10.21037/tlcr-19-396. Transl Lung Cancer Res. 2020. PMID: 32953484 Free PMC article.
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes.
Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, Song Y, Li H, Zhou C. Meng S, et al. Among authors: zhou w, zhou c. Nanotechnology. 2010 Oct 15;21(41):415103. doi: 10.1088/0957-4484/21/41/415103. Epub 2010 Sep 17. Nanotechnology. 2010. PMID: 20852356
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Zhou C, et al. Among authors: zhou s. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. Lancet Oncol. 2011. PMID: 21783417 Clinical Trial.
EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.
Schmid-Bindert G, Wang Y, Jiang H, Sun H, Henzler T, Wang H, Pilz LR, Ren S, Zhou C. Schmid-Bindert G, et al. Among authors: zhou c. PLoS One. 2013 Oct 29;8(10):e77948. doi: 10.1371/journal.pone.0077948. eCollection 2013. PLoS One. 2013. PMID: 24205040 Free PMC article.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Among authors: zhou c. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples.
Zhao C, Li X, Li J, Zhang Y, Ren S, Chen X, Zhou C. Zhao C, et al. Among authors: zhou c. Transl Oncol. 2014 Jun 17;7(3):363-7. doi: 10.1016/j.tranon.2014.04.013. eCollection 2014 Jun. Transl Oncol. 2014. PMID: 25180059 Free PMC article.
19,389 results
You have reached the last available page of results. Please see the User Guide for more information.